CD8A and neoplasm: In this study, we developed a therapeutic erythrocyte drug conjugated with MHC-I protein fused with HPV16 E6/E7 antigen peptide and demonstrated its robust capacity to activate antigen-specific CD8+ T cells and specifically enhance their cytotoxicity against tumor cells from HPV+ cancer patients in vitro.